Monoclonal antibodies based on hybridoma technology

Author： Yagami Hisanori   Kato Hiroshi   Tsumoto Kanta   Tomita Masahiro  

Publisher： Future Science

ISSN： 2046-8954

Source： Pharmaceutical Patent Analyst, Vol.2, Iss.2, 2013-03, pp. : 249-263

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Monoclonal antibodies

By Drakeman D.L.   Wallace P.K.  

Expert Opinion on Emerging Drugs, Vol. 4, Iss. 1, 1999-01 ,pp. : 355-365

Informa Healthcare

Access to resources Recommend Favorite

Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies

By Cao Yanguang   Balthasar Joseph   Jusko William  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 40, Iss. 5, 2013-10 ,pp. : 597-607

Springer Publishing Company

Access to resources Recommend Favorite

Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies

By Du Lanying   Jiang Shibo  

Future Virology, Vol. 5, Iss. 2, 2010-03 ,pp. : 141-144

Future Medicine

Access to resources Recommend Favorite

Monoclonal Antibodies in Solid Tumours

By  

Current Clinical Pharmacology, Vol. 5, Iss. 3, 2010-08 ,pp. : 160-165

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal Antibodies - Regulatory Challenges

By  

Current Pharmaceutical Biotechnology, Vol. 9, Iss. 6, 2008-12 ,pp. : 431-438

Bentham Science Publishers

Access to resources Recommend Favorite